ArticleCancer medicine2026
Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile overall survival for chronic myeloid leukemia (CML) at 5 years now exceeds 90% with modern tyrosine kinase inhibitor (TKI) therapies, disparities in management and outcomes persist among underserved populations. This study describes TKI treatment patterns and outcomes in a predominantly Hispanic, underserved CML cohort treated at Los Angeles County safety-net hospitals.
methodsWe performed a retrospective chart review of 108 adult patients with CML who presented to Los Angeles County hospitals between 2015 and 2024. Data collected included demographics, comorbidities, treatment selection per line of therapy (LOT), and major molecular response (MMR; > 3-log reduction) rates.
resultsThe majority (58.3%) of patients were Hispanic, and most (59.2%) lived in zip codes with household incomes below the national average. The median age at diagnosis was 46 years old, and 82.4% of patients had comorbid conditions at diagnosis, including elevated BMI (67.5%), hypertension (28.7%), and diabetes (20.4%). By EUTOS score, 55.6% of patients were low-risk, and 11.1% were high-risk. Imatinib was the most common first-line treatment for 64.8% of patients, followed by 31.5% with dasatinib. MMR was achieved in 44.4% of patients, while 43.5% of patients discontinued first-line LOT due to medication intolerance. Overall, 56.5% of patients progressed to second LOT and 27% required third LOT.
conclusionsDespite a younger median age at diagnosis, our patients had less favorable outcomes compared to previously published cohorts including lower rates of MMR with first-line therapy, higher rates of toxicity, and needing more lines of therapy overall. These findings highlight the need for further investigation into the socioeconomic, biologic, and treatment-access factors impacting outcomes in underserved patients with CML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.